(Q45181403)

10 December 2017

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? (English)

1 reference

10 December 2017

2

Tommaso Susini

1 reference

10 December 2017

7

Gianfranco Scarselli

1 reference

10 December 2017

Maria Rosaria Raspollini

1

1 reference

10 December 2017

Gianni Amunni

3

1 reference

10 December 2017

Milena Paglierani

4

1 reference

10 December 2017

Antonio Taddei

5

1 reference

10 December 2017

Mauro Marchionni

6

1 reference

10 December 2017

Gian Luigi Taddei

8

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

10 December 2017

1 reference

10 December 2017

96

1 reference

10 December 2017

1

1 reference

10 December 2017

159-167

1 reference

Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients

10 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Mixed tumors and carcinosarcomas of the uterus evaluated five years after treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Management of malignant, mixed mesodermal tumors of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Uterine carcinosarcoma is derived from a single stem cell: an in vitro study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

The kit ligand: A cell surface molecule altered in steel mutant fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Smooth muscle, endometrial stromal, and mixed Müllerian tumors of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.050

10.1016/J.YGYNO.2004.09.050

7 January 2021

Identifiers

DOI

1 reference

10 December 2017

1 reference